Full Press Release Details
Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study.
ZLAB
Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study
Key Takeaway: Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study
Price reaction · baseline $26.75 (2025-11-03 close) · hit after-hours · 2 other ZLAB headline(s) in the window, move may be shared
day 0 close · peak
-3.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer